BERKELEY HEIGHTS, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational product EG-1962 for the treatment of subarachnoid hemorrhage (SAH).